Supported By: Tandem Diabetes Care, Inc.

Program Description

In this product theater, Jordan Pinsker, Chief Medical Officer for Tandem Diabetes Care, will discuss the latest automated insulin delivery innovation, the Tandem Mobi system.

Tandem Mobi, the world’s smallest, durable automated insulin delivery system,1 became commercially available in the United States in February of 2024.

Tandem Mobi is powered by Control-IQ technology, which can help keep glucose levels in range by using CGM* values to predict glucose levels 30 minutes ahead and automatically adjusting insulin delivery every five minutes. It also leverages an automatic correction bolus, that can be optimized by the user by simply changing correction factor.†

Tandem Mobi is fully controllable via a mobile app and is so small that it can be worn almost anywhere,‡ giving greater discretion, comfort, and options for how people with diabetes manage their therapy.

This product theater will feature Dr. Halis Kaan Akturk, Associate Professor of Medicine and Pediatrics at the Barbara Davis Center for Diabetes, University of Colorado, who will offer valuable insights about the early, real-world experience with Tandem Mobi. Additionally, Cari Berget, MPH, RN, CDE, Director of the PANTHER Program and Research Instructor in Pediatrics at the Barbara Davis Center, will discuss how the unique wearability features of Tandem Mobi, combined with the Control-IQ technology algorithm, ushers in a new generation for AID systems. The speakers will also discuss the benefits of a small-sized insulin system that can be disconnected for sports, swimming, and real-life scenarios, and how optimizing algorithm settings can help improve patient outcomes.

Tandem will also share details about the future of its AID and the pursuit of fully closed-loop systems.

* CGM sold separately. † If glucose values are predicted to be above 180 mg/dL, Control-IQ technology calculates a correction bolus using the Personal Profile settings and a target of 110 mg/dL and delivers 60% of that value. ‡ Do not wear or place your pump more than 12 inches (30.5 cm) above your infusion site. Doing so may result in over delivery of insulin

Reference: 1. As of June, 2024. Data on file, Tandem Diabetes Care.

RX ONLY. Indicated for patients with type 1 diabetes, 6 years and older. WARNING: Control-IQ technology should not be used by people under age 6, or who use less than 10 units of insulin/day, or who weigh less than 55 lbs. Safety info: tandemdiabetes.com/safetyinfo

This information is being distributed by the American Diabetes Association as a sponsor benefit. Reference to commercial products, processes, or services by trade name, trademark, manufacturer, or otherwise, does not necessarily constitute or imply its endorsement, recommendation, or favoring by the American Diabetes Association. The views and opinions of sponsors expressed herein do not necessarily state or reflect those of the American Diabetes Association, and shall not be used for advertising or product endorsement purposes.

Speakers

Jordan Pinsker, MD
Tandem Diabetes Care, Inc.
Chief Medical Officer
Santa Barbara, CA

Halis K. Akturk, MD
Barbara Davis Center for Diabetes
Associate Professor of Pediatrics and Medicine
Aurora, CO

Cari Berget, RN, MPH, CDCES
University of Colorado
Instructor
Aurora, CO